Day: May 8, 2025

ALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2025. First Quarter Financial ResultsFirst quarter revenue was $48.6 million, a 17.4% increase compared to the first quarter of 2024. For the first quarter of 2025, gross margin was 71.9%, down from 78.8% for the first quarter of 2024. Net loss for the quarter was $3.8 million, or $0.08 per share, compared to $6.6 million, or $0.15 per share for the first quarter of 2024. Adjusted net loss for the quarter was $0.9 million, or $0.02 per share, compared to $2.7 million, or $0.06 per share, for the first quarter of 2024. Adjusted EBITDA was $2.9...

Cloud subscriptions revenue increased 15% year-over-year to $99.8 million and generated operating cash flow of $45.0 million MCLEAN, Va., May 08, 2025 (GLOBE NEWSWIRE) — Appian (Nasdaq: APPN) today announced financial results for the first quarter ended March 31, 2025. “In Q1, Appian continued to demonstrate our earnings potential, with narrowing net losses, our third straight quarter of positive adjusted EBITDA, and $45 million in operating cash flow,” said Matt Calkins, CEO & Founder. First Quarter 2025 Financial Highlights:Revenue: Cloud subscriptions revenue was $99.8 million, up 15% compared to the first quarter of 2024. Total subscriptions revenue, which includes sales of our cloud subscriptions, on-premises term license subscriptions, and maintenance and support, increased 14% year-over-year to $134.4 million. Professional...

– WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year – – First patient dosed in the Phase 1b/2 clinical trial of WTX-330, seeking to build on the clinical activity and tolerability demonstrated in the recently completed WTX-330 first-in-human Phase 1 trial – – Company announces development of its proprietary INDUCER™ T cell engager molecules; development candidate targeted by the end of the second quarter of 2025 – – Updated cash guidance provides runway into the fourth quarter of 2026 – WATERTOWN, Mass., May 08, 2025 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune...

Initiation of Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 2Q25; deep and sustained benefits observed through Month 12 after a single course of therapy in Phase 2b trial Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus expected in 2H25 Initiation of Phase 2 pediatric basket trial of Descartes-08 in select autoimmune indications expected in 2H25 Approximately $182.1 million cash, cash equivalents and restricted cash as of March 31, 2025 expected to support planned operations into mid-2027, including completion of planned Phase 3 AURORA trial FREDERICK, Md., May 08, 2025 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today reported financial results...

Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat rheumatoid arthritis to initiate in Q2 2025 CLN-978 expands into Sjögren’s disease; Phase 1 study in active, moderate to severe patients to initiate in the U.S. in Q2 2025 Zipalertinib REZILIENT1 results to be shared in oral presentation at 2025 ASCO Annual Meeting CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) — Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today reported recent and anticipated business highlights and announced its financial results for the first quarter ended March 31, 2025. “As a leader in T cell engager development for autoimmune diseases, we continue to rapidly advance our global clinical development...

First Quarter Revenue was $559.2 million, a 14.0% increase over the prior year periodGross margin increased 25.9% to $183.6 million compared to Q1 2024First Quarter Net income was $5.2 million compared to net loss of $11.2 million for the comparable prior year periodAdjusted Net income was $21.4 million, an increase of $27.1 million compared to Q1 2024Adjusted EBITDA for Q1 2025 was $67.4 million, a 93.1% increase as compared to Q1 2024 Revised Full Year 2025 Revenue guidance greater than $2.15 billion, updated from a range of $2.10 – $2.12 billionRevised Full Year 2025 Adjusted EBITDA guidance greater than $207 million, updated from a range of $190 – $194 millionATLANTA, May 08, 2025 (GLOBE NEWSWIRE) — Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused...